|
So shouldn't this be taken into consideration when studying chemobrain?
I do not fully understand this study and why they gave people scopolamine. But I think that they're saying that the younger group benefited from the addition of estrogen while the older group did not, as it related to cognitive function. So it might be the same for deprivation - more consequences for those who are perimenopausal? And if that's true, then don't you think that they should be considering AI use to be a confounder when they study chemobrain? And don't you wish that they'd mention these questions to women considering taking an AI? Especially those women for whom an AI offers only a small increased benefit?
Debbie Laxague
|
Threaded Mode